Cargando…
Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib
BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal disease among female genital malignant tumors. Peptidylarginine deiminase type II(PADI II) has been shown to enhance a variety of cancers carcinogenesis, including ovarian cancer. The purpose of this study was to investigate the biologic...
Autores principales: | Liu, Lidong, Zhang, Zhiwei, Zhang, Guoxiang, Wang, Ting, Ma, Yingchun, Guo, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504643/ https://www.ncbi.nlm.nih.gov/pubmed/32951601 http://dx.doi.org/10.1186/s12967-020-02528-0 |
Ejemplares similares
-
Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016) -
PADI4-mediated epithelial-mesenchymal transition in lung cancer cells
por: Liu, Meiyan, et al.
Publicado: (2019) -
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas
por: Colomiere, M, et al.
Publicado: (2009) -
Ribonucleotide reductase subunit M2 promotes proliferation and epithelial–mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma
por: Yang, Min, et al.
Publicado: (2021) -
Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)